Table 4.

Effect modification of the relationship between HDL cholesterol and risk of death by presence of coronary artery disease

eGFR (ml/min per 1.73 m2) with or without Coronary Artery DiseaseHazard Ratio (95% Confidence Interval)
HDL-C≤25 mg/dlHDL-C>25 to <34 mg/dlHDL-C≥34 to ≤42 mg/dlHDL-C>42 to <50 mg/dlHDL-C≥50 mg/dl
≥15 to <30
 Without1.000.92 (0.83 to 1.02)0.92 (0.83 to 1.02)0.96 (0.86 to 1.07)0.97 (0.87 to 1.09)
 With1.000.91 (0.85 to 0.97)0.88 (0.82 to 0.93)0.89 (0.83 to 0.96)0.98 (0.91 to 1.05)
≥30 to <45
 Without1.000.84 (0.79 to 0.89)0.82 (0.77 to 0.87)0.81 (0.76 to 0.86)0.85 (0.80 to 0.91)
 With1.000.90 (0.86 to 0.93)0.87 (0.84 to 0.91)0.85 (0.81 to 0.89)0.89 (0.85 to 0.93)
≥45 to <60
 Without1.000.84 (0.80 to 0.88)0.81 (0.77 to 0.84)0.80 (0.77 to 0.84)0.85 (0.81 to 0.89)
 With1.000.86 (0.83 to 0.89)0.84 (0.81 to 0.87)0.82 (0.79 to 0.85)0.88 (0.85 to 0.92)
≥60 to <90
 Without1.000.84 (0.82 to 0.87)0.80 (0.78 to 0.83)0.81 (0.79 to 0.84)0.88 (0.86 to 0.91)
 With1.000.89a (0.87 to 0.92)0.86a (0.84 to 0.89)0.87a (0.84 to 0.89)0.93a (0.90 to 0.96)
≥90
 Without1.000.81 (0.78 to 0.85)0.80 (0.77 to 0.83)0.80 (0.77 to 0.84)0.96 (0.92 to 1.00)
 With1.000.93a (0.87 to 0.98)0.92a (0.87 to 0.98)0.94a (0.88 to 0.99)1.08a (1.02 to 1.14)
  • Models were adjusted for age, race, cancer, cerebrovascular accident, chronic lung disease, diabetes mellitus, dementia, hepatitis C, HIV, hypertension, body mass index, LDL cholesterol, triglycerides, serum albumin, angiotensin–converting enzyme inhibitor/angiotensin receptor blocker use, coronary artery disease, congestive heart failure, and peripheral artery disease. Models were additionally adjusted for eGFR, dialysis, kidney transplant, and statin use as time varying. HDL-C, HDL cholesterol.

  • a Significant (<0.05) P value for interaction between HDL-C level and coronary artery disease status.